TWiV 1138: Clinical update with Dr. Daniel Griffin

This Week in Virology

In his weekly clinical update, Dr. Griffin discusses the harms of perpetuating the lab leak hypothesis and the recent ACIP recommendations for the RSV vaccine for those individuals over 60, before reviewing the recent statistics on SARS-CoV-2 infection, treatment guidelines for the different phases of COVID, including vaccines, Pemgarda, early treatment with Paxlovid, remdesivir and molnupiravir, steroids at the right time, anticoagulation support, immune modulation in some cases, and a comprehensive definition of long COVID.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Harms of the lab leak hypothesis (Journal of Virology)
• Lab leak mania (PaulOffit, Substack)
• This is a special message: pandemic started in nature! (TWiV)
• RSV vaccine recommendations August 6 2024 (MMWR)
• COVID-19 national trend (CDC)
• COVID-19 deaths (CDC)
• Where to get Pemgarda (Pemgarda)
• CDC Quarantine guidelines (CDC)
• Early phase of SARs-CoV-2 infection (COVID.gov)
• NIH COVID-19 treatment guidelines (NIH)
• Infectious Disease Society guidelines for treatment and management (ID Society)
• Drug interaction checker (University of Liverpool)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendation for immunocompromised (ID Society)
• Managing healthcare staffing shortages (CDC)
• Steroids,dexamethasone at the right time (OFID)
• Anticoagulation guidelines (hematology.org) Long COVID defined (NEJM)
• Contribute to our Floating Doctors fundraiser
• Lenacapavir on Puscast #60
• Letters read on TWiV 1138
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [e-mail]